Biologic modulators in allergic and autoinflammatory diseases

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 4, 2011, Pages 355-360

  Broderick, Lori ^a   Tourangeau, Louanne M ^a   Kavanaugh, Arthur ^a   Wasserman, Stephen I ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

allergy; autoinflammatory; biologics; monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; AMYLOID; C REACTIVE PROTEIN; CANAKINUMAB; CD23 ANTIGEN; CYTOKINE ANTIBODY; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6 RECEPTOR; LUMILIXIMAB; MEPOLIZUMAB; OMALIZUMAB; PREDNISONE; RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RESLIZUMAB; RILONACEPT; TALIZUMAB; TOCILIZUMAB;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTHRALGIA; ASTHMA; ATOPY; AUTOINFLAMMATORY DISEASE; CHOLINERGIC NERVE; CHURG STRAUSS SYNDROME; CINCA SYNDROME; CLOSED ANGLE GLAUCOMA; COLD URTICARIA; CYTOMEGALOVIRUS REACTIVATION; CYTOPENIA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FEVER; FOLLOW UP; FOOD ALLERGY; GASTROINTESTINAL DISEASE; HEAT URTICARIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION; INFECTION RISK; INFLAMMATION; INFUSION REACTION; INJECTION SITE REACTION; LIVER FUNCTION TEST; LOW DRUG DOSE; LYMPHOMA; MALIGNANCY; MUCKLE WELLS SYNDROME; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NOSE POLYP; PEANUT ALLERGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESSURE URTICARIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; REVIEW; SEVERE PERSISTENT ASTHMA; SIDE EFFECT; SOLAR URTICARIA; SUBCUTANEOUS IMMUNOTHERAPY; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; URTICARIA; VERTIGO; VIRAL UPPER RESPIRATORY TRACT INFECTION;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DOUBLE-BLIND METHOD; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOMA; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CYTOKINE; RECOMBINANT FUSION PROTEINS; RESPIRATORY HYPERSENSITIVITY; TRANSLATIONAL RESEARCH;

EID: 79960839205     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328348a882     Document Type: Review

References (41)

1. Tourangeau LM, Kavanaugh A, Wasserman SI, The role of monoclonal antibodies in the treatment of severe asthma, Ther Adv Respir Dis, 2011. DOI: 10.1177/1753465811400489. This review highlights many of the current and developing therapies for patients with asthma.
2. Lee S, Ballow M, Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases, J Allergy Clin Immunol 2010; 125:814-820.
3. Hashkes PJ, Uziel Y, Laxer RM, The safety profile of biologic therapies for juvenile idiopathic arthritis, Nat Rev Rheumatol 2010; 6:561-571.
4. Hoffman HM, Therapy of autoinflammatory syndromes, J Allergy Clin Immunol 2009; 124:1129-1138. An excellent review of immunomodulatory therapy for autoinflammatory syndromes with a focus on anti-IL-1 treatments.
5. Masters SL, Simon A, Aksentijevich I, Kastner DL, Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease, Annu Rev Immunol 2009; 27:621-668
6. Lepore L, Paloni G, Caorsi R, et al, Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra, J Pediatr 2010; 157:310-315.
7. Neven B, Marvillet I, Terrada C, et al, Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010; 62:258-267.
8. Hoffman HM, Simon A, Recurrent febrile syndromes: what a rheumatologist needs to know, Nat Rev Rheumatol 2009; 5:249-256
9. Obici L, Meini A, Cattalini M, et al, Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis, Ann Rheum Dis 2010, doi: 10.1136/ard.2010.143438. This study is about first large series of TRAPS patients treated with anakinra.
10. Vaitla PM, Radford PM, Tighe PJ, et al, Role of interleukin-6 (IL-6) in a patient with TRAPS revealed by treatment with tocilizumab (anti-IL-6 receptor monoclonal antibody), Arthritis Rheum 2011; 63:1151-1155.
11. Poole JA, Meng J, Reff M, et al, Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects, J Allergy Clin Immunol 2005; 116:780-788. (Pubitemid 41400542)
12. Rosenwasser LJ, Meng J, Anti-CD23, Clin Rev Allergy Immunol 2005; 29:61-72. (Pubitemid 41434104)
13. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, Use of canakinumab in the cryopyrin-associated periodic syndrome, N Engl J Med 2009; 360:2416-2425.
14. Busse WW, Ring J, Huss-Marp J, Kahn JE, A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010; 125:803-813. A review of the role of IL-5 and potential for therapy of hypereosinophilia and asthma with mepolizumab.
15. Straumann A, Conus S, Grzonka P, et al, Antiinterleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebocontrolled, double-blind trial, Gut 2010; 59:21-30
16. Rothenberg ME, Klion AD, Roufosse FE, et al, Treatment of patients with the hypereosinophilic syndrome with mepolizumab, N Engl J Med 2008; 358:1215-1228. (Pubitemid 351439223)
17. Schwartz LB, Sheikh J, Singh A, Current strategies in the management of hypereosinophilic syndrome, including mepolizumab, Curr Med Res Opin 2010; 26:1933-1946.
18. Rosenwasser LJ, Rothenberg ME, IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome, J Allergy Clin Immunol 2010; 125:1245-1246.
19. Verstovsek S, Tefferi A, Kantarjian H, et al, Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia, Clin Cancer Res 2009; 15:368-373.
20. Economides AN, Carpenter LR, Rudge JS, et al, Cytokine traps: multicomponent, high-affinity blockers of cytokine action, Nat Med 2003; 9:47-52. (Pubitemid 36098259)
21. Lee SJ, Chinen J, Kavanaugh A, Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins, J Allergy Clin Immunol 2010; 125 (2 Suppl 2):S314-S323
22. Church LD, Churchman SM, Hawkins PN, McDermott MF, Hereditary autoinflammatory disorders and biologics, Springer Semin Immunopathol 2006; 27:494-508.
23. Simsek I, Kaya A, Erdem H, et al, No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy, J Nephrol 2010; 23:119-123.
24. Hoffman HM, Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS), Expert Opin Biol Ther 2009; 9:519-531.
25. Hoffman HM, Throne ML, Amar NJ, et al, Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies, Arthritis Rheum 2008; 58:2443-2452.
26. Milgrom H, Fick RB Jr, Su JQ, et al, Treatment of allergic asthma with monoclonal anti-IgE antibody: rhuMAb-E25 Study Group, N Engl J Med 1999; 341:1966-1973. (Pubitemid 30010404)
27. Chervinsky P, Casale T, Townley R, et al, Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis, Ann Allergy Asthma Immunol 2003; 91:160-167. (Pubitemid 36999475)
28. Casale TB, Stokes J, Anti-IgE therapy: clinical utility beyond asthma, J Allergy Clin Immunol 2009; 123:770.e1-771.e1.
29. Kamin W, Kopp MV, Erdnuess F, et al, Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously, Pediatr Allergy Immunol 2010; 21 (1 Pt 2): e160-e165.
30. Magerl M, Staubach P, Altrichter S, et al, Effective treatment of therapyresistant chronic spontaneous urticaria with omalizumab, J Allergy Clin Immunol 2010; 126:665-666.
31. Bindslev-Jensen C, Skov PS, Efficacy of omalizumab in delayed pressure urticaria: a case report, Allergy 2010; 65:138-139.
32. Bullerkotte U, Wieczorek D, Kapp A, Wedi B, Effective treatment of refractory severe heat urticaria with omalizumab, Allergy 2010; 65:931-932.
33. Metz M, Altrichter S, Ardelean E, et al, Antiimmunoglobulin E treatment of patients with recalcitrant physical urticaria, Int Arch Allergy Immunol 2011; 154:177-180.
34. Sabroe RA, Failure of omalizumab in cholinergic urticaria, Clin Exp Dermatol 2010; 35:e127-e129.
35. Pitt TJ, Cisneros N, Kalicinsky C, Becker AB, Successful treatment of idiopathic anaphylaxis in an adolescent, J Allergy Clin Immunol 2010; 126:415-416.
36. Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG, Omalizumab monotherapy for bee sting and unprovoked 'anaphylaxis' in a patient with systemic mastocytosis and undetectable specific IgE, Ann Allergy Asthma Immunol 2010; 104:537-539.
37. Dreyfus DH, Randolph CC, Characterization of an anaphylactoid reaction to omalizumab, Ann Allergy Asthma Immunol 2006; 96:624-627.
38. Rafi A, Do LT, Katz R, et al, Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010; 31:76-83.
39. Leung DYM, Sampson HA, Yunginger JW, et al, Effect of anti-IgE therapy in patients with peanut allergy, N Engl J Med 2003; 348:986-993. (Pubitemid 36302243)
40. Brownell J, Casale TB, Anti-IgE therapy, Immunol Allergy Clin North Am 2004; 24:551-568. (Pubitemid 39330307)
41. Weiner LM, Surana R, Wang S, Monoclonal antibodies: versatile platforms for cancer immunotherapy, Nat Rev Immunol 2010; 10:317-327.